免疫檢查點抑制劑導致免疫相關性肺炎_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

周巧 , YU He ,  LIANG Zong’An

四川大學華西醫院呼吸與危重癥醫學科（四川成都 ?610041）;

Corresponding?author：

LIANG Zong’An, Email: liang.zongan@163.com

Keywords：

DOI：

10.7507/1671-6205.201912018

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： YU He, LIANG Zong’An. 免疫檢查點抑制劑導致免疫相關性肺炎. Chinese Journal of Respiratory and Critical Care Medicine, 2021, 20(10): 753-756. doi: 10.7507/1671-6205.201912018 Copy

1.	Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol, 2016, 39(1): 98-106.
2.	Keir ME, Liang SC, Guleria I, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med, 2006, 203(4): 883-895.
3.	Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med, 2002, 8(8): 793-800.
4.	Hwang WL, Pike LRG, Royce TJ, et al. Safety of combining radiotherapy with immune-checkpoint inhibition. Nat Rev Clin Oncol, 2018, 15(8): 477-494.
5.	Braschi-Amirfarzan M, Tirumani SH, Hodi FS Jr, et al. Immune-checkpoint inhibitors in the era of precision medicine: what radiologists should know. Korean J Radiol, 2017, 18(1): 42-53.
6.	Sosa A, Lopez Cadena E, Simon Olive C, et al. Clinical assessment of immune-related adverse events. Ther Adv Med Oncol, 2018, 10: 1758835918764628.
7.	King GT, Sharma P, Davis SL, et al. Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy. Drugs Today (Barc), 2018, 54(2): 103-122.
8.	Cramer P, Bresalier RS. Gastrointestinal and hepatic complications of immune checkpoint inhibitors. Curr Gastroenterol Rep, 2017, 19(1): 3.
9.	Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer, 2016, 60: 190-209.
10.	Uchida M, Nakamura T, Shima T, et al. Comparative quantification of chemotherapy-induced nausea and emesis between the common terminology criteria for adverse events and the multinational association of supportive care in cancer antiemesis tool. Biol Pharm Bull, 2018, 41(11): 1667-1671.
11.	Suresh K, Psoter KJ, Voong KR, et al. Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy. J Thorac Oncol, 2019, 14(3): 494-502.
12.	Eigentler TK, Hassel JC, Berking C, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev, 2016, 45: 7-18.
13.	Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol, 2018, 4(12): 1721-1728.
14.	Nishino M, Sholl LM, Hodi FS, et al. Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med, 2015, 373(3): 288-290.
15.	Nishino M, Giobbie-Hurder A, Hatabu H, et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol, 2016, 2(12): 1607-1616.
16.	Balaji A, Verde F, Suresh K, et al. Pneumonitis from anti-PD-1/PD-L1 therapy. Oncology (Williston Park), 2017, 31(10): 739-746.
17.	Cupp J, Culakova E, Poniewierski MS, et al. Analysis of factors associated with in-hospital mortality in lung cancer chemotherapy patients with neutropenia. Clin Lung Cancer, 2018, 19: e163-e169.
18.	Chuzi S, Tavora F, Cruz M, et al. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Manag Res, 2017, 9: 207-213.
19.	Hassel JC, Heinzerling L, Aberle J, et al. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): evaluation and management of adverse drug reactions. Cancer Treat Rev, 2017, 57: 36-49.
20.	Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med, 2017, 377(14): 1345-1356.
21.	Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol, 2016, 17(7): 883-895.
22.	Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol, 2016, 17(11): 1558-1568.
23.	Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med, 2015, 372(21): 2006-2017.
24.	Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol, 2017, 35(7): 709-717.
25.	Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med, 2018, 378(2): 158-168.
26.	Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med, 2015, 373(13): 1270.
27.	Xiao Y, Yu S, Zhu B, et al. RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J Exp Med, 2014, 211(5): 943-959.
28.	Su Q, Zhu EC, Wu JB, et al. Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors: a systematic review and meta-analysis. Front Immunol, 2019, 10: 108.
29.	Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med, 2013, 188(6): 733-748.
30.	Nishino M, Ramaiya NH, Awad MM, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res, 2016, 22(24): 6051-6060.
31.	Mueller-Mang C, Grosse C, Schmid K, et al. What every radiologist should know about idiopathic interstitial pneumonias. Radiographics, 2007, 27(3): 595-615.
32.	Porcu M, De Silva P, Solinas C, et al. Immunotherapy associated pulmonary toxicity: biology behind clinical and radiological featuree. Cancers (Basel), 2019, 11(3): 305.
33.	Kadoch MA, Cham MD, Beasley MB, et al. Idiopathic interstitial pneumonias: a radiology-pathology correlation based on the revised 2013 American Thoracic Society-European Respiratory Society classification system. Curr Probl Diagn Radiol, 2015, 44(1): 15-25.
34.	Berthod G, Lazor R, Letovanec I, et al. Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol, 2012, 30(17): e156-159.
35.	Dimitriou F, Frauchiger AL, Urosevic-Maiwald M, et al. Sarcoid-like reactions in patients receiving modern melanoma treatment. Melanoma Res, 2018, 28(3): 230-236.
36.	Firwana B, Ravilla R, Raval M, et al. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors. J Oncol Pharm Pract, 2017, 23(8): 620-624.
37.	Chow LQ. Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer. Am Soc Clin Oncol Educ Book, 2013, 33: e280.
38.	Abdel-Rahman O, Fouad M. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Ther Adv Respir Dis, 2016, 10(3): 183-193.
39.	Sehgal S, Velcheti V, Mukhopadhyay S, et al. Focal lung infiltrate complicating PD-1 inhibitor use: a new pattern of drug-associated lung toxicity?. Respir Med Case Rep, 2016, 19: 118-120.
40.	Delaunay M, Cadranel J, Lusque A, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J, 2017, 50(2): pii1700050.
41.	Li H, Ma W, Yoneda KY, et al. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report. Journal of Hematology & Oncology, 2017, 10(1): 64.
42.	Koelzer VH, Rothschild SI, Zihler D, et al. Systemic inflammation in a melanoma patient treated with immune check-point inhibitors-an autopsy study. J Immunother Cancer, 2016, 4: 13.
43.	Fishman JA, Hogan JI, Maus MV. Inflammatory and infectious syndromes associated with cancer immunotherapies. Clin Infect Dis, 2019, 69(6): 909-920.
44.	Bala-Hampton JE, Bazzell AF, Dains JE. Clinical management of pneumonitis in patients receiving anti-PD-1/PD-L1 therapy. J Adv Pract Oncol, 2018, 9(4): 422-428.
45.	Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer, 2017, 5(1): 95.
46.	Friedman CF, Proverbs-Singh TA, et al. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol, 2016, 2(10): 1346-1353.
47.	Haanen JBAG, Carbonnel F, Robert C, et al. Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Ann Oncol, 2018, 29(4): 264-266.
48.	Petri CR, Patell R, Batalini F, et al. Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: case report and review of the literature. Respir Med Case Rep, 2019, 27: 100834.
49.	Hallowell RW, Amariei D, Danoff SK. Intravenous immunoglobulin as potential adjunct therapy for interstitial lung disease. Ann Am Thorac Soc, 2016, 13(10): 1682-1688.
50.	Simonaggio A, Michot JM, Voisin AL, et al. Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol, 2019, 5(9): 1310-1317.
51.	Helmy KY, Patel SA, Nahas GR, et al. Cancer immunotherapy: accomplishments to date and future promise. Ther Deliv, 2013, 4(10): 1307-1320.

1. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol, 2016, 39(1): 98-106.
2. Keir ME, Liang SC, Guleria I, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med, 2006, 203(4): 883-895.
3. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med, 2002, 8(8): 793-800.
4. Hwang WL, Pike LRG, Royce TJ, et al. Safety of combining radiotherapy with immune-checkpoint inhibition. Nat Rev Clin Oncol, 2018, 15(8): 477-494.
5. Braschi-Amirfarzan M, Tirumani SH, Hodi FS Jr, et al. Immune-checkpoint inhibitors in the era of precision medicine: what radiologists should know. Korean J Radiol, 2017, 18(1): 42-53.
6. Sosa A, Lopez Cadena E, Simon Olive C, et al. Clinical assessment of immune-related adverse events. Ther Adv Med Oncol, 2018, 10: 1758835918764628.
7. King GT, Sharma P, Davis SL, et al. Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy. Drugs Today (Barc), 2018, 54(2): 103-122.
8. Cramer P, Bresalier RS. Gastrointestinal and hepatic complications of immune checkpoint inhibitors. Curr Gastroenterol Rep, 2017, 19(1): 3.
9. Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer, 2016, 60: 190-209.
10. Uchida M, Nakamura T, Shima T, et al. Comparative quantification of chemotherapy-induced nausea and emesis between the common terminology criteria for adverse events and the multinational association of supportive care in cancer antiemesis tool. Biol Pharm Bull, 2018, 41(11): 1667-1671.
11. Suresh K, Psoter KJ, Voong KR, et al. Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy. J Thorac Oncol, 2019, 14(3): 494-502.
12. Eigentler TK, Hassel JC, Berking C, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev, 2016, 45: 7-18.
13. Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol, 2018, 4(12): 1721-1728.
14. Nishino M, Sholl LM, Hodi FS, et al. Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med, 2015, 373(3): 288-290.
15. Nishino M, Giobbie-Hurder A, Hatabu H, et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol, 2016, 2(12): 1607-1616.
16. Balaji A, Verde F, Suresh K, et al. Pneumonitis from anti-PD-1/PD-L1 therapy. Oncology (Williston Park), 2017, 31(10): 739-746.
17. Cupp J, Culakova E, Poniewierski MS, et al. Analysis of factors associated with in-hospital mortality in lung cancer chemotherapy patients with neutropenia. Clin Lung Cancer, 2018, 19: e163-e169.
18. Chuzi S, Tavora F, Cruz M, et al. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Manag Res, 2017, 9: 207-213.
19. Hassel JC, Heinzerling L, Aberle J, et al. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): evaluation and management of adverse drug reactions. Cancer Treat Rev, 2017, 57: 36-49.
20. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med, 2017, 377(14): 1345-1356.
21. Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol, 2016, 17(7): 883-895.
22. Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol, 2016, 17(11): 1558-1568.
23. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med, 2015, 372(21): 2006-2017.
24. Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol, 2017, 35(7): 709-717.
25. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med, 2018, 378(2): 158-168.
26. Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med, 2015, 373(13): 1270.
27. Xiao Y, Yu S, Zhu B, et al. RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J Exp Med, 2014, 211(5): 943-959.
28. Su Q, Zhu EC, Wu JB, et al. Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors: a systematic review and meta-analysis. Front Immunol, 2019, 10: 108.
29. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med, 2013, 188(6): 733-748.
30. Nishino M, Ramaiya NH, Awad MM, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res, 2016, 22(24): 6051-6060.
31. Mueller-Mang C, Grosse C, Schmid K, et al. What every radiologist should know about idiopathic interstitial pneumonias. Radiographics, 2007, 27(3): 595-615.
32. Porcu M, De Silva P, Solinas C, et al. Immunotherapy associated pulmonary toxicity: biology behind clinical and radiological featuree. Cancers (Basel), 2019, 11(3): 305.
33. Kadoch MA, Cham MD, Beasley MB, et al. Idiopathic interstitial pneumonias: a radiology-pathology correlation based on the revised 2013 American Thoracic Society-European Respiratory Society classification system. Curr Probl Diagn Radiol, 2015, 44(1): 15-25.
34. Berthod G, Lazor R, Letovanec I, et al. Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol, 2012, 30(17): e156-159.
35. Dimitriou F, Frauchiger AL, Urosevic-Maiwald M, et al. Sarcoid-like reactions in patients receiving modern melanoma treatment. Melanoma Res, 2018, 28(3): 230-236.
36. Firwana B, Ravilla R, Raval M, et al. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors. J Oncol Pharm Pract, 2017, 23(8): 620-624.
37. Chow LQ. Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer. Am Soc Clin Oncol Educ Book, 2013, 33: e280.
38. Abdel-Rahman O, Fouad M. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Ther Adv Respir Dis, 2016, 10(3): 183-193.
39. Sehgal S, Velcheti V, Mukhopadhyay S, et al. Focal lung infiltrate complicating PD-1 inhibitor use: a new pattern of drug-associated lung toxicity?. Respir Med Case Rep, 2016, 19: 118-120.
40. Delaunay M, Cadranel J, Lusque A, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J, 2017, 50(2): pii1700050.
41. Li H, Ma W, Yoneda KY, et al. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report. Journal of Hematology & Oncology, 2017, 10(1): 64.
42. Koelzer VH, Rothschild SI, Zihler D, et al. Systemic inflammation in a melanoma patient treated with immune check-point inhibitors-an autopsy study. J Immunother Cancer, 2016, 4: 13.
43. Fishman JA, Hogan JI, Maus MV. Inflammatory and infectious syndromes associated with cancer immunotherapies. Clin Infect Dis, 2019, 69(6): 909-920.
44. Bala-Hampton JE, Bazzell AF, Dains JE. Clinical management of pneumonitis in patients receiving anti-PD-1/PD-L1 therapy. J Adv Pract Oncol, 2018, 9(4): 422-428.
45. Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer, 2017, 5(1): 95.
46. Friedman CF, Proverbs-Singh TA, et al. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol, 2016, 2(10): 1346-1353.
47. Haanen JBAG, Carbonnel F, Robert C, et al. Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Ann Oncol, 2018, 29(4): 264-266.
48. Petri CR, Patell R, Batalini F, et al. Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: case report and review of the literature. Respir Med Case Rep, 2019, 27: 100834.
49. Hallowell RW, Amariei D, Danoff SK. Intravenous immunoglobulin as potential adjunct therapy for interstitial lung disease. Ann Am Thorac Soc, 2016, 13(10): 1682-1688.
50. Simonaggio A, Michot JM, Voisin AL, et al. Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol, 2019, 5(9): 1310-1317.
51. Helmy KY, Patel SA, Nahas GR, et al. Cancer immunotherapy: accomplishments to date and future promise. Ther Deliv, 2013, 4(10): 1307-1320.

Previous Article
CXC型趨化因子及其受體軸在慢性阻塞性肺疾病中的研究進展
Next Article
染料試驗在氣管切開患者誤吸評估中的研究進展

Chinese Journal of Respiratory and Critical Care Medicine

免疫檢查點抑制劑導致免疫相關性肺炎

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content